John P. Butler's most recent trade in Akebia Therapeutics Inc. was a trade of 46,409 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on March 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.83 per share. | 03 Mar 2025 | 46,409 | 2,557,921 (2%) | 0% | 1.8 | 84,928 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 1,051,400 | 1,051,400 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 701,000 | 2,748,580 (2%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 350,500 | 350,500 | - | - | Performance Stock Units | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 2.10 per share. | 31 Jan 2025 | 97,982 | 2,604,330 (2%) | 0% | 2.1 | 205,762 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 2.10 per share. | 31 Jan 2025 | 46,268 | 2,702,312 (2%) | 0% | 2.1 | 97,163 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.58 per share. | 29 Feb 2024 | 46,570 | 2,044,580 (1%) | 0% | 1.6 | 73,581 | Common Stock |
| Akebia Therapeutics Inc | Butler P. John | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.52 per share. | 27 Feb 2024 | 37,733 | 2,091,150 (1%) | 0% | 1.5 | 57,354 | Common Stock |
| Akebia Therapeutics Inc | John Butler P. | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 905,200 | 905,200 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | Butler P. John | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 603,500 | 2,175,372 (1%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | P. Butler John | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 31 Jan 2024 | 46,489 | 2,128,883 (1%) | 0% | 1.7 | 78,102 | Common Stock |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 71,736 | 71,736 | - | - | Stock Option (right to buy) | |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 47,824 | 80,880 (0%) | 0% | 0 | Common Stock | |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Sale of securities on an exchange or to another person at price $ 0.35 per share. | 13 Jun 2023 | 115 | 80,765 (0%) | 0% | 0.3 | 40 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 47,239 | 1,575,242 (1%) | 0% | 0.9 | 41,452 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 38,259 | 1,622,481 (1%) | 0% | 0.9 | 33,572 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 6,370 | 1,568,872 (1%) | 0% | 0.9 | 5,590 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 27 Feb 2023 | 38,632 | 1,660,740 (1%) | 0% | 0.8 | 31,416 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 875,000 | 875,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 635,313 | 635,313 | - | - | Stock Appreciation Right | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 293,125 | 1,699,372 (1%) | 0% | 0 | Common Stock | |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 34,663 | 34,663 | - | - | Stock Option (right to buy) | |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 23,109 | 33,109 (0%) | 0% | 0 | Common Stock | |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Sale of securities on an exchange or to another person at price $ 1.02 per share. | 14 Jun 2022 | 53 | 33,056 (0%) | 0% | 1.0 | 54 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 739,700 | 739,700 | - | - | Employee Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 293,125 | 1,457,220 (1%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 2.15 per share. | 28 Feb 2022 | 25,053 | 1,164,095 (0%) | 0% | 2.2 | 53,984 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 25,031 | 1,407,378 (1%) | 0% | 2.2 | 54,335 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 24,811 | 1,432,409 (1%) | 0% | 2.2 | 53,857 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 4,131 | 1,403,247 (1%) | 0% | 2.2 | 8,967 | Common Stock |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Zynerba Pharmaceuticals Inc | John P. Butler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 5,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 01 Apr 2021 | 4,109 | 1,152,153 (0%) | 0% | 3.4 | 13,971 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 39,520 | 1,156,262 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 403,600 | 403,600 | - | - | Employee Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 237,400 | 1,166,732 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 26 Feb 2021 | 25,316 | 1,141,416 (0%) | 0% | 3.4 | 85,976 | Common Stock |
| Akebia Therapeutics Inc | John P. Butler | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 26 Feb 2021 | 24,674 | 1,116,742 (0%) | 0% | 3.4 | 83,795 | Common Stock |